000
| 01543cam 2200373zi 4500 |
---|
001 | 9.912786 |
---|
003 | CaOODSP |
---|
005 | 20220912101905 |
---|
006 | m o d f |
---|
007 | cr mn||||||||| |
---|
008 | 220627e202208 onc ob f000 0 eng d |
---|
020 | |a9780660442617 |
---|
040 | |aCaOODSP|beng|erda|cCaOODSP |
---|
043 | |an-cn--- |
---|
086 | 1 |aH164-277/2022E-PDF |
---|
245 | 00|aGuidance document : |bthe management of drug submissions and applications. |
---|
264 | 1|aOttawa, ON : |bHealth Canada = Santé Canada,|cAugust 2022. |
---|
264 | 4|c©2022 |
---|
300 | |a1 online resource (74 pages) |
---|
336 | |atext|btxt|2rdacontent |
---|
337 | |acomputer|bc|2rdamedia |
---|
338 | |aonline resource|bcr|2rdacarrier |
---|
500 | |aIssued also in French under title: Ligne directrice : gestion des présentations et des demandes de drogues. |
---|
500 | |a"Pub.: 220295." |
---|
500 | |aIssued also in HTML format. |
---|
504 | |aIncludes bibliographical references. |
---|
650 | 0|aDrug approval|zCanada. |
---|
650 | 0|aPharmaceutical policy|zCanada. |
---|
710 | 1 |aCanada. |bHealth Canada, |eissuing body. |
---|
775 | 08|tLigne directrice : |w(CaOODSP)9.912785 |
---|
795 | |tGuidance document : |w(CaOODSP)9.901130 |
---|
856 | 40|qPDF|s676 KB|uhttps://publications.gc.ca/collections/collection_2022/sc-hc/H164-277-2022-eng.pdf |
---|
856 | 4 |qHTML|sN/A|uhttps://www.canada.ca/en/health-canada/services/drugs-health-products/drug-products/applications-submissions/guidance-documents/management-drug-submissions/industry/document.html |
---|